Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415026 | 0.83 | HCAR2 (0.52) | HCAR2POLBCYP2C9ACKR3KMT2A | |
| SCHEMBL9307990 | 0.81 | KDM4E (0.53) | NPC1RAB9AATMPOLBCNR2 | |
| SCHEMBL2930614 | 0.79 | THRB (0.59) | NPC1RAB9ACNR2CNR1KMT2A | |
| SCHEMBL2090351 | 0.75 | GAA (0.52) | NPC1RAB9AATMPOLBCNR2 | |
| SCHEMBL12294711 | 0.75 | NPC1 (0.50) | NPC1RAB9AATMCNR2CNR1 | |
| SCHEMBL19877014 | 0.75 | NPC1 (0.46) | HCAR2NPC1RAB9AATMPOLB | |
| SCHEMBL621869 | 0.74 | POLB (0.71) | NPC1RAB9AATMPOLBCNR2 | |
| SCHEMBL22018098 | 0.73 | HCAR2 (0.57) | HCAR2 | |
| SCHEMBL1880894 | 0.73 | KDM4E (0.61) | HCAR2POLB | |
| SCHEMBL6023280 | 0.73 | NPC1 (0.54) | NPC1RAB9AATMPOLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1278167-A | Amide derivatives | SUMITOMO PHARMA (JP) | 2000-12-27 | — | — | CN | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | HCAR2 57/4885NPC1 300/4885RAB9A 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.